BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS

Registry ID

EUCTR2010-020545-26

Source registry

EUCTR

Status

Ongoing

Phase

PHASE2

Sponsor

AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE

Start date

2008-12-09

Last update

2026-08-16

Conditions

• HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Summary

� To evaluate the efficacy of bevacizumab for treatment of severe chronic nasal and/or gastrointestinal bleeding in HHT patients. � To establish the most effective dosage, according to a risk/benefit ratio.

Locations

• , , Italy

View on source registry